Central Monitoring Summit

Successfully introducing new drugs and therapies in a quicker and more cost-effective manner starts in the most complex phase on of drug development; the clinical phase. The implementation of risk-based monitoring increases the overall quality of data while providing better oversight of patient safety. With the introduction of centralized monitoring in a risk-based monitoring approach, pharmaceutical companies are able to embrace a real-time overview of data and risk detection.

Read More

View Less